The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?

Nitin Jain; Susan O'Brien

doi:10.1097/PPO.0000000000000417

The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?

Nitin Jain, Susan O'Brien

Leukemia

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.

Original language	English (US)
Pages (from-to)	374-377
Number of pages	4
Journal	Cancer Journal (United States)
Volume	25
Issue number	6
DOIs	https://doi.org/10.1097/PPO.0000000000000417
State	Published - Nov 1 2019

Keywords

CLL
chemotherapy
targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/PPO.0000000000000417

Cite this

@article{b065ec80534640db933b3c7c46220834,

title = "The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?",

abstract = "Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.",

keywords = "CLL, chemotherapy, targeted therapy",

author = "Nitin Jain and Susan O'Brien",

year = "2019",

month = nov,

day = "1",

doi = "10.1097/PPO.0000000000000417",

language = "English (US)",

volume = "25",

pages = "374--377",

journal = "Cancer Journal (United States)",

issn = "1528-9117",

publisher = "Association Pour le Developpement de la Communication Cancerologique",

number = "6",

}

TY - JOUR

T1 - The Shifting Paradigm in Chronic Lymphocytic Leukemia

T2 - Is Chemotherapy Still Relevant?

AU - Jain, Nitin

AU - O'Brien, Susan

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.

AB - Chemoimmunotherapy (CIT) was the standard treatment for patients with chronic lymphocytic leukemia for the last 2 decades. Recently, with the introduction of targeted therapies, the role of CIT has declined significantly. In the first-line setting, the role of CIT is limited to young fit patients with mutated immunoglobulin heavy chain variable region and without del(17p)/TP53 mutation. There is a limited role for CIT in relapsed chronic lymphocytic leukemia.

KW - CLL

KW - chemotherapy

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85075506483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075506483&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000417

DO - 10.1097/PPO.0000000000000417

M3 - Review article

C2 - 31764117

AN - SCOPUS:85075506483

SN - 1528-9117

VL - 25

SP - 374

EP - 377

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

IS - 6

ER -

The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this